The particulars: 5 mg · survodutide.
I would like the mechanism, because I want to be able to reason about the cases nobody has written about.
I have tried to reason it out from first principles and got to two contradictory conclusions.
So what is the mechanism, and how well established is it?
Two administrations of 2.5 mg instead of one of 5 mg — the same 5 mg a week either way. Total weekly exposure is unchanged; what changes is the peak-to-trough ratio, and for an agent with a half-life measured in days the trough barely moves because the dosing interval is already short relative to it. The arithmetic is the easy part: 5 ÷ 2 = 2.5. Whether it is worth doing is a pharmacokinetic question, and nothing here is medical advice.
The honest answer is that reported tolerability benefits are real to the people reporting them and are not well explained by the exposure profile.
For a drug with elimination half-life t½ dosed at interval τ, the peak-to-trough ratio at steady state is 2^(τ/t½). With a one-week half-life dosed weekly, τ/t½ = 1, so the ratio is 2 — a factor of two between peak and trough, which is already flat by pharmacological standards.
Halving a dose accurately requires the reading resolution to support it. A 10-unit dose split into two 5-unit doses is at the coarse end of any barrel.
Titration schedules in the trial programmes were designed to manage gastrointestinal tolerability and are the evidenced approach to that problem.
The caveat is that no split schedule has been evaluated in a trial, so the whole discussion is inference plus report.
Work out 2^(τ/t½) for your agent before arguing about this. It usually settles it.
edited 20 Jul 2024 by orla_ferriter — added a caveat about sampling
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsAnswering this needs the specific agent, because the answer for a thirteen-hour half-life and a one-week half-life are opposite.
For a thirteen-hour half-life agent dosed daily, τ/t½ is about 1.8 and the swing is nearly fourfold, which is why the daily agents feel peakier and why splitting them would have more effect.
It helps to be literal here: each additional injection is an additional stopper entry, an additional needle and an additional opportunity to introduce contamination into a preparation that has no release testing behind it.
No trial in this class has evaluated a split schedule against the licensed one, so any comparison is anecdotal.
More injections means more handling risk, and that cost is certain while the benefit is not.
Slower titration has evidence; splitting has anecdote. Prefer the first.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.